20 per cent upper circuit: Heavy buying witnessed in this multibagger stock post announcing stellar results!

The stock has witnessed significant buying activity as it has given multibagger returns of more than 590 per cent in 3 years

On Monday, shares of Dr Agarwal Eye Hospital zoomed and got locked at 20 per cent upper circuit to trade on intraday high of Rs 1394.24 apiece on BSE. The scrip witnessed massive spurt in volume by more than 6.5 times.   

The audited financial results for the quarter and year ended March 31, 2023 showing significant growth for the company compared to the previous fiscal year. The total income for the year ended March 2023 was Rs 269.65 crore, up by 33.17 per cent from the previous year's total income of Rs 202.47 crore. The EBITDA for the year ended March 2023 was Rs. 49.40 crore, which is a YoY jump of 52.93 per cent from the previous year's EBITDA of Rs 32.31 crore.   

The net profit for the year ended March 2023 was Rs. 36.11 crore, up by 49.79 per cent from the previous year's net profit of Rs. 24.10 crore. These impressive YoY jumps demonstrate the company's growth and success in its operations.  

Moreover, the company announced a final dividend of Rs 3 per equity share of Rs 10 each fully paid-up, equivalent to 30 per cent of the face value, for the financial year 2022-23. However, this dividend is subject to the approval of the members at the upcoming Annual General Meeting.  

DSIJ offers a product 'multibagger Pick" with recommendations for multi-bagger stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the product details pdf here

Dr Agarwal's Eye Hospital is a leading eye care provider in India. Established in 1957, the hospital has been providing comprehensive eye care services for over 60 years. It is known for its state-of-the-art infrastructure, advanced technology and experienced ophthalmologists. The hospital offers a wide range of eye care services including cataract surgery, LASIK surgery, glaucoma treatment, corneal transplant and paediatric ophthalmology.  

The stock has witnessed significant buying activity as it has given multibagger returns of more than 590 per cent in 3 years. Moreover, the stock has rallied more than 90 per cent in the past 1 year. Keep a close eye in this trending multibagger stock.